The nation’s newest health care campus fosters collaboration among students, researchers and clinicians. Campus architecture and state-of-the-art technology bridge education and research with two world-class hospitals: University of Colorado Hospital and The Children’s Hospital.
The Anschutz Medical Campus in Aurora is the world's only completely new education, research and patient care facility and is the largest academic health center between Chicago, Texas and the West Coast.
Built as state-of-the-art, the campus consists of three zones that promote collaboration and innovation: an education zone with remarkable facilities for training future physicians and other health professionals; a research zone with ground-breaking, internationally renowned research; and, nearby, a clinical-care zone with the University of Colorado Hospital and The Children's Hospital, the University of Colorado School of Medicine's primary adult and pediatric hospital partners.
- More than 500,000 patients a year served
- Industry partners located in the adjacent Colorado Science and Technology Park at Fitzsimons
- Site totals 227 acres of land including clinical, research and education “zones”
- Development investments of $2 billion will ultimately attract more than $4 billion in facility-related funding
- At present, 3.4 million gross square feet of cutting-edge education, patient care and research space
- A model across the nation for the successful redevelopment of a decommissioned army facility
The Anschutz Medical Campus uniquely positions the university to change lives, save lives and build futures.
In 2006, in recognition of a series of gifts totaling $91 million by The Anschutz Foundation, the University of Colorado Denver announced that its Aurora campus would be named the Anschutz Medical Campus. The new name recognizes the significant contributions made by the foundation to the university and University of Colorado Hospital. Recently, the foundation donated an additional $15 million to create a Health and Wellness Center—a soon-to-be-built center designed to foster a new culture of health promotion and disease prevention on a campus that includes hospitals, research facilities and a complete set of health sciences programs, from nursing to medicine to public health.
An impressive track record in research
School of Medicine researchers have a proven record of success and expertise in innovation, discovery and commercialization of therapies, drugs and medical devices. With a reputation for delivering results, our 2,000 outstanding faculty members have already begun translating basic sciences into medical breakthroughs that are helping people around the world:
- First to develop a classification and numbering system for human chromosomes
- First to identify a genetic factor that converts normal cells into cancer cells
- First to learn that lymphocytes are preprogrammed to respond to antigens, the foundation of modern immunology
- First to learn how a human cancer gene functions
- First to learn that naturally occurring proteins in the blood prevent the AIDS virus from reproducing and spreading to healthy cells
- Identifier of the first gene that carries the risk of schizophrenia
- Identifier of key molecular mechanisms in the failing human heart that have led to successful development of effective therapies
In 2007, more than $373 million in research and training grants and contracts was awarded to University of Colorado Denver researchers.
Accelerating industry to drive growth
Colorado and the Denver metro area rank fifth in the nation for commitment to technology industry growth (source: Colorado Bioscience Association) There are more than 400 bioscience companies in the Denver metro area employing more than 16,000 professionals. Agilent, Amgen, ARCA Biopharma, Array Biopharma, Dharmacon, Gilead Sciences, GlobeImmune, Replidyne and Roche are just a few of the successful companies that reside in Colorado.
Some of these promising enterprises have been purchased by larger companies, greatly expanding and accelerating the distribution of new therapies to patients.